Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data

References

• 2013 USRDS Annual Data Report: atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Volume II. Atlas of end-stage renal disease in the United States: mortality. Am J Kidney Dis 2013;63(Suppl 1):e263-70
   Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208-18
   PubMed Web of Science ®Google Scholar
• Hutchinson A. Oral phosphate binders. Kidney Int 2009;75:906-14
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Delmez J, Block GA, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68(6):386-91
   PubMed Web of Science ®Google Scholar
• St. Peter WL, Fan Q, Weinhandl E, et al. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. J Am Soc Nephrol 2009;4:1954-61
   Web of Science ®Google Scholar
• Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif 2005;23(Suppl 1):2-11
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68(6):2809-13
   PubMed Web of Science ®Google Scholar
• Umanath K, Niecestro R, Lewis JB, et al. Ferric Citrate: a novel phosphate-binding agent. Expert Rev Endocrinol Metab 2013;8(1):13-19
   PubMedGoogle Scholar
• Van Wyck DB. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Dial 1989;9(2):21-8
   Google Scholar
• Sinsakul M, Sika M, Koury M, et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012;121:c25-9
   PubMed Web of Science ®Google Scholar
• Dwyer JP, Sika M, Schulman G, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013;61(5):759-66
   PubMed Web of Science ®Google Scholar
• Lewis JB, Sika M, Koury M, et al. Ferric citrate controls serum phosphorus and delivers iron to end-stage renal disease patients. J Am Soc Nephrol 2014; doi: 10.1681/ASN.2014020212
   Web of Science ®Google Scholar
• Koury M, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr 2004;24:105-31
   PubMed Web of Science ®Google Scholar
• Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012;366(4):348-59
   PubMed Web of Science ®Google Scholar
• Yang WC, Yang CS, Hou CC, et al. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002;17(2):265-70
   PubMed Web of Science ®Google Scholar
• A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD). 2008. Available from: https://clinicaltrials.gov/ct2/show/NCT00648167?term=keryx&rank=7 [Last accessed 10 July 2014]
   Google Scholar
• A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period. 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT01074125?term=keryx&rank=5 [Last accessed 10 July 2014]
   Google Scholar
• A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis. 2010. Available from: https://clinicaltrials.gov/ct2/show/NCT01191255?term=keryx&rank=6 [Last accessed 10 July 2014]
   Google Scholar
• Umanath K, Sika M, Niecestro R, et al. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 2013;17(1):67-74
   PubMed Web of Science ®Google Scholar
• Middleton JP, Athreya B, Ayodeji O, et al. Ferric citrate, a phosphate binder, increases iron stores but is not associated with evidence of the malnutrition-inflammation-cachexia syndrome (abstract). J Am Soc Nephrol 2013;24:90A
   Google Scholar
• A Long-Term Safety Extension Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01554982?term=keryx&rank=8 [Last accessed 10 July 2014]
   Google Scholar
• Rodby R, Umanath K, Hsieh A. Phosphorus Binding with ferric citrate reduces erythropoiesis-stimulating agent (ESA) and IV iron usage and cost in patients with ESRD. Am J Kid Dis 2014;63(5):B118
   Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-S201
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130
   PubMedGoogle Scholar
• Porter M. What is Value in Health Care? N Engl J Med 2010.363:2477-81
   Google Scholar